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Abstract
Background: Generalized arterial alterations, such as endothelial dysfunction, medial matrix accumulations, and
calcifications are associated with type 2 diabetes (T2D). These changes may render the vessel wall more susceptible
to injury; however, the molecular characteristics of such diffuse pre-atherosclerotic changes in diabetes are only
superficially known.
Methods: To identify the molecular alterations of the generalized arterial disease in T2D, DNA microarrays were
applied to examine gene expression changes in normal-appearing, non-atherosclerotic arterial tissue from 10
diabetic and 11 age-matched non-diabetic men scheduled for a coronary by-pass operation. Gene expression
changes were integrated with GO-Elite, GSEA, and Cytoscape to identify significant biological pathways and
networks.
Results: Global pathway analysis revealed differential expression of gene-sets representing matrix metabolism,
triglyceride synthesis, inflammation, insulin signaling, and apoptosis. The network analysis showed a significant
cluster of dysregulated genes coding for both intra- and extra-cellular proteins associated with vascular cell
functions together with genes related to insulin signaling and matrix remodeling.
Conclusions: Our results identify pathways and networks involved in the diffuse vasculopathy present in non-
atherosclerotic arterial tissue in patients with T2D and confirmed previously observed mRNA-alterations. These
abnormalities may play a role for the arterial response to injury and putatively for the accelerated atherogenesis
among patients with diabetes.
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Background
Cardiovascular diseases (CVD) in patients with type 2 dia-
betes are a large and increasing health problem. Increased
atherosclerotic lesions are believed to form the basis
behind the high frequency of CVD in diabetes; however,
epidemiological studies have shown that traditional risk
factors, e.g. hypertension and dyslipidemia cannot explain
the increased incidence [1]. Unfortunately, the molecular
mechanisms leading to atherosclerosis in diabetes are only
partially understood [2].
The arterial wall in diabetes harbors not only increased
amounts of atherosclerotic plaques, but also diffuse altera-
tions present in non-atherosclerotic parts of the vessel
wall. One element of the generalized alterations in the
vasculature in diabetes is endothelial dysfunction [3], char-
acterized by increased permeability [4], increased expres-
sion of pro-inflammatory molecules [5], and altered
vasomotoric responses [6]. Moreover, changes in extracel-
lular matrix components of the tunica media are present
in both atherosclerotic and non-atherosclerotic parts of
the arterial tree in diabetes. Increased concentrations of
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any medium, provided the original work is properly cited.collagen type 4 [7], hyaluronic acid [8], osteopontin, osteo-
protegerin [9], and metalloproteinases [10] have, for exam-
ple, been described in conjunction with the presence of
high amounts of glucose-derived increased cross-linking
of collagens [11]. Decreased amounts of several gene pro-
ducts related to apoptosis have been observed in vascular
smooth muscle cells from normal appearing areas of
arteries from patients with diabetes [12]. In addition, linear
media calcifications occur with increased frequency
among patients with glucose intolerance and diabetes and
are strong predictors of CVD in these individuals [13,14].
In accordance, recent studies of non-atherosclerotic arter-
ial alterations in animal models of type 2 diabetes and
hyperglycemia demonstrated increased aortic stiffness and
upregulation of matrix components [15], increased arterial
calcification [16], and accumulation of glycosaminoglycan-
rich material [17]. Thus, defects in several molecular path-
ways seem to be present in the arterial wall in patients
with type 2 diabetes. These changes are likely to play
important roles in the arterial response to injury and thus
in the build-up of atherosclerotic plaques in diabetic
patients.
By using DNA microarrays for transcriptional profiling,
a large number of genes can be analyzed simultaneously
and the resulting data can be integrated with pathways
and biological interaction networks to detect coordinated
changes in functionally related genes. Recently, we applied
gene expression microarrays and identified fibulin-1
(FBLN1) as a molecular marker of cardiovascular disease
in non-atherosclerotic tissue from patients with type 2 dia-
betes [18]. To our knowledge, only one other study has
examined global gene expression changes in arterial tissue
from diabetic patients; however, the results only reflected
different degrees of atherosclerosis and not specific dia-
betes related alterations [19].
In the present study, we hypothesized that diffuse dia-
betes-related alterations in non-atherosclerotic arterial tis-
sue are associated with a cluster of dysregulated genes
involved in vascular and metabolic cell functions. We
applied global pathway and network analysis to unravel
t h eg e n ee x p r e s s i o np r o f i l eo fw e l l - d e f i n e d ,n o r m a l -
appearing arterial tissue from patients with type 2 diabetes.
Methods
Subjects
Study subjects were recruited from patients undergoing
artery by-pass graft surgery at Skejby and Odense Univer-
sity Hospital. Participants included ten men with more
than 2 years known duration of type 2 diabetes, defined
as diabetes diagnosed after adolescence, and eleven non-
diabetic men matched according to age (Table 1). Partici-
pants and tissue handling have been described in a study
aimed at identifying single genes differentially expressed
in type 2 diabetes [18]. Briefly, a small piece of arteria
mammaria interna from all patients was dissected into
intima-media and surrounding tissue and frozen in liquid
nitrogen within a few minutes. The arteries are spare
material from the repair vessel from coronary by-pass
operations. The investigation was approved by the local
Danish ethical committee in Region Mid and South and
informed consent was obtained from each subject.
Histology
Tissue for histology was fixed for 24-72 hours in PBS-buf-
fered 4% formaldehyde and subsequently embedded in
paraffin. Sections were cut and stained by hematoxylin-
eosin, von kossa, and elastin using routine methods [18].
RNA isolation and microarray hybridization
Total RNA was isolated and hybridized to microarrays as
previously described [18]. Briefly, total RNA was isolated
from intima-media samples by using the TRIzol protocol
(Life Technologies, Gaithersburg, MD, USA), and purified
RNA was converted to biotin-labeled amplified RNA
(aRNA) and hybridized to Affymetrix HG-U133A 2.0
chips (Affymetrix, Santa Clara, CA, USA).
Data processing and statistical analysis
All microarray chips were preprocessed as reported pre-
viously [18]. The regularized t-test limma http://www.
bioconductor.org was applied to evaluate differences in
gene expression between patients with diabetes and con-
trol subjects. Genes with an uncorrected P <0 . 0 5w e r e
considered for further analysis.
Global pathway and network analysis
Changes in gene expression at the pathway level
between diabetic patients and control subjects were
assessed using GO-Elite 1.19 http://www.genmapp.org/
go_elite/ and Gene Set Enrichment Analysis (GSEA)
2.0.1 [20]. GO-Elite is a software tool that runs an
updated version of MAPPFinder [21] and filters redun-
dant pathways. A total of 113 pathways were analyzed
Table 1 Characteristics of diabetic patients and control
subjects
Diabetic
patients
Control
subjects
N1 0 1 1
Age (years) 65.6 ± 11.9 65.2 ± 8.5
Systolic blood pressure (mmHg) 143.1 ± 35.6 153.9 ± 16.6
Diastolic blood pressure (mmHg) 76.3 ± 11.6 87.9 ± 8.7
†
Hemoglobin A1c (fract.) 0.074 ± 0.01 0.060 ± 0.004
††
Total cholesterol (mmol/l) 4.1 ± 0.8 4.7 ± 0.5
High Density Lipoprotein (mmol/
l)
1.2 ± 0.2 1.4 ± 0.3
Data represent means ± SD; Students T-test for non-paired data used.
†P <
0.05 and
††P < 0.005 for diabetic patients vs. control subjects
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way, and 2000 permutations were applied to assess the
significance of the z-score http://www.genmapp.org.
Applying the MSigDB database http://www.broad.mit.
edu/gsea/msigdb in GSEA, we compiled an “artery gene
set” consisting of 820 gene sets and pathways. All genes
were ranked according to the ttest and an enrichment
score (ES) was assigned to each gene set. The statistical
significance of the ES was estimated by performing 2000
gene permutations. After gene set enrichment analysis
in GSEA, we masked the redundant gene sets by using
the leading edge analysis option http://www.broad.mit.
edu/gsea.
Gene expression changes between diabetic patients and
control subjects were integrated with molecular interac-
tion networks using Cytoscape 2.6.0 [22]. The Human
Interactome data set http://www.cytoscape.org/cgi-bin/
moin.cgi/Data_Sets, composed of 61,263 protein-protein
interactions analogous to 10,000 different proteins, was
loaded into the Cytoscape software. To reduce the com-
plexity of the large network, differentially expressed genes
f r o mt h ed a t as e t( P < 0.05) were mapped onto the net-
work, and then the filter option in Cytoscape was used to
select proteins (nodes) interacting directly with the differ-
entially expressed genes generating a new network. To
identify hubs–i.e. interacting nodes with high network
degrees assumed to correspond to essential gene products
in the cell [23]–with 15 or more interactions, the topology
filter option was applied to the new network creating a
smaller network. The jActiveModules plugin in Cytoscape
was applied to the small network to identify a subnetwork
with an overall significant response to the experimental
condition. The anneal algorithm and 250.000 iterations
were used in the jActiveModules plugin to identify the
subnetwork. A z-score was calculated for the subnetwork
and the significance of the z-score was assessed by per-
forming 1000 permutations. NetworkAnalyzer is a core
plugin in Cytoscape and has been used to calculate topolo-
gical values for each gene in the subnetwork.
Results
The mean age of the study subjects was 65 years (Table 1).
Patients with type 2 diabetes had elevated hemoglobin A1c
(P < 0.005) and reduced diastolic blood pressure (P <
0.05). There was no difference between the two groups
with respect to systolic blood pressure, HDL, and total
cholesterol as previously reported [18].
Histology
Tissue from all subjects appeared normal, i.e. without
atherosclerosis, calcified areas, or cellular infiltrations, as
revealed by von kossa, hematoxylin-eosin, and elastin
staining as previously reported [18]. In a few instances,
enough tissue was obtained to make additional histology
after dissection to control the separation of intima-media
from adventitia. In these cases, dissection was made just
outside the lamina elastica externa.
Global gene expression analysis
Of the 22,277 probe sets represented on the array, 477
were downregulated and 169 were upregulated in type 2
diabetic patients versus control subjects as reported pre-
viously (P < 0.05) [18]. No probe sets were significantly
differentially expressed after controlling for multiple
hypothesis testing using the Benjamini-Hochberg method
[24].
Analysis of gene sets and biological pathways
To examine the difference in gene expression between the
two groups at the pathway level, data were loaded into
GSEA 2.0.1 and GO-Elite 1.19. Applying GSEA, caries
pulp up (genes upregulated in pulpal tissue from carious
teeth) [25], neuroactive ligand receptor interaction, cell
adhesion molecules, monocyte dend DN (genes downre-
gulated in monocyte dendritic cells), and cytokine-cyto-
kine receptor interaction were the most significantly
upregulated gene sets (FWER < 0.05). The most signifi-
cantly downregulated gene sets included kidney transplant
well UP [26], insulin 2F UP (genes 2 fold upregulated in
muscle by insulin) [27], heartfailure atria DN, GH
GHRHR KO 24 hrs DN [28], proteasome, and diab neph
DN (genes downregulated in the glomeruli of cadaver kid-
neys from patients with diabetic nephropathy) (FWER <
0.05) (Table 2). Further description of the gene sets can be
found in the MsigDB database http://www.broad.mit.edu/
gsea/msigdb.
The statistical rating of the results in GO-Elite was pro-
vided by the z-score, and pathways with a z-score above
2.0 were considered significant [21]. Evaluation of the
results revealed significant upregulation of triacylglyceride
synthesis, apoptosis, matrix metalloproteinases, and adipo-
genesis (z > 2.0). Five pathways including cholesterol bio-
synthesis, TNF-alpha NFkB Netpath 9, Krebs TCA Cycle,
non-homologous end joining, and signaling of hepatocyte
growth factor receptor were significantly downregulated
(z > 2.0) (Table 3).
Computational analysis of the Human Interactome
network
To further explore the global gene expression changes
associated with arterial disease in type 2 diabetes, data
were integrated with the Human interactome network to
identify the principal subnetworks i.e. connected regions
of the network that show significant changes in expres-
sion. 397 differentially expressed genes (P < 0.05) from
the microarray data set interacted directly with 2980 pro-
teins (nodes) in the network creating a network com-
posed of 3227 interacting nodes. Filtering of hubs with
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of 1043 nodes. Performing jActiveModules on the 1043
node network unveiled 5 highly overlapping subnetworks,
therefore, we decided only to focus on the top network
consisting of 74 nodes (z = 9.23) (permute P = 0.01). The
statistically significant 74 node subnetwork is depicted in
Figure 1. Topological values and number of interactors
for all genes are shown in Table 4. The topological coeffi-
cient is a relative measure for the extent to which a node
shares neighbors with other nodes. The most important
cardiometabolic hubs and their interactors are shown in
Table 5.
Table 2 Ranking of the top 10 up- and downregulated gene sets using GSEA in intima-media of type 2 diabetic
patients vs. control subjects
GENE SET SIZE ES NES NOM FDR FWER
p-value p-value p-value
Upregulated gene sets
Caries pulp UP 202 -0.43 -2.29 < 0.0001 0.0006 0.0005
HSA04080 Neuroactive ligand receptor interaction 227 -0.42 -2.27 < 0.0001 0.0009 0.002
HSA04514 Cell adhesion molecules 114 -0.43 -2.18 < 0.0001 0.002 0.005
Monocyte dend DN 115 -0.43 -2.13 < 0.0001 0.003 0.01
HSA04060 Cytokine-cytokine receptor interaction 225 -0.39 -2.12 < 0.0001 0.003 0.01
Kidney transplant rejection UP 80 -0.45 -2.09 < 0.0001 0.004 0.02
HSA04610 Complement and coagulation cascades 63 -0.45 -2.05 < 0.0001 0.007 0.04
HSA01430 Cell communication 108 -0.41 -2.02 < 0.0001 0.008 0.05
HSA04640 Hematopoietic cell lineage 83 -0.43 -2.01 < 0.0001 0.008 0.06
Osteoclasts sig 37 -0.50 -1.94 < 0.0001 0.02 0.13
Downregulated gene sets
Kidney transplant well UP 251 0.56 2.45 < 0.0001 < 0.0001 < 0.0001
Insulin 2F UP 167 0.57 2.41 < 0.0001 < 0.0001 < 0.0001
Heartfailure atria DN 109 0.55 2.20 < 0.0001 0.0002 0.0005
GH GHRHR KO 24 hrs DN 140 0.53 2.18 < 0.0001 0.0001 0.0005
HSA03050 Proteasome 21 0.73 2.16 < 0.0001 0.0002 0.001
Diab neph DN 249 0.49 2.15 < 0.0001 0.0002 0.001
HSA00190 Oxidative phosphorylation 99 0.55 2.15 < 0.0001 0.0001 0.001
Kidney transplant well PBL DN 40 0.61 2.09 < 0.0001 0.0005 0.004
Krebs TCA cycle 29 0.65 2.07 < 0.0001 0.0008 0.008
mRNA processing 41 0.61 2.07 0.0007 0.0008 0.009
Ranking of the gene sets was done using GSEA 2.0.1. ES, enrichment score; NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate; FWER,
family wise error rate
Table 3 Ranking of up- and downregulated pathways in intima-media of type 2 diabetic patients vs. control subjects
using GO-Elite 1.19
MAPP Name Changed Measured On MAPP Changed Z Permute FWER
(n) (n) (n) (%) score p-value p-value
Upregulated pathways
Triacylglyceride synthesis 3 22 24 13.64 4.7 0.002 0.23
Apoptosis 4 83 85 4.82 2.5 0.04 0.67
Matrix metalloproteinases 2 30 32 6.67 2.4 0.04 0.67
Adipogenesis 5 129 133 3.88 2.3 0.04 0.67
Downregulated pathways
Cholesterol biosynthesis 4 15 15 26.67 4.8 0.004 0.15
TNFalpha NFkB netpath 9 16 187 208 8.56 3.8 0.003 0.15
Krebs TCA cycle 5 32 39 15.63 3.7 0.007 0.18
Non-homologous end joining 2 7 8 28.57 3.6 0.04 0.61
Signaling of hepatocyte growth factor receptor 5 35 36 14.29 3.5 0.02 0.39
Shown are significantly up- and downregulated pathways in intima-media of diabetic patients vs. control subjects. Only non-redundant pathways with a z-score
above 2.0 are listed. A foldchange of 1.05 and a p-value < 0.05 were used as filtering criteria. Changed (n): number of changed genes, Measured (n): number of
genes on the chip, On MAPP (n): number of genes on the MAPP, Changed (%): percentage of changed genes, FWER: family wise error rate
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In the present study, we used high-density oligonucleo-
tide arrays to elucidate global gene expression patterns in
non-atherosclerotic, non-calcified, normal-appearing
arterial tissue from patients with type 2 diabetes. Pre-
viously, we used these data in a study aimed at identifying
new molecular markers of arterial disease in type 2 dia-
betes. Examinations were done at the single gene level
with microarrays, and we were able to validate several
genes with q-RT-PCR including FBLN1 as significantly
upregulated in the vascular wall both at the mRNA and
protein level [18]. In the present bioinformatic study, we
use our mRNA expression data to explore biological
pathways and networks that are dysregulated in the arter-
ial wall in diabetes. Although our data indicate that dif-
ferences in gene expression between arterial tissue from
patients with diabetes and non-diabetic subjects are mod-
est at the single gene level [18], we demonstrate that
clusters of highly interconnected genes are significantly
dysregulated at the transcriptional level in arterial tissue
in diabetes. Providing credibility to our results, a number
of gene products of these pathways has previously been
found dysregulated in the vessel wall in diabetic vasculo-
pathy, as discussed below.
The results from GSEA demonstrate significant upre-
gulation of gene sets and pathways related to cytokine-
growth factor- and hormonal actions in arterial tissue
from diabetic individuals. This include the gene sets car-
ies pulp up, cell adhesion molecules, monocyte dend
DN, and cytokine-cytokine receptor interaction with
caries pulp up as the most significantly upregulated
gene set. Interestingly, there is an increasing evidence
supporting an association between periodontitis and dia-
betic complications [29,30] suggesting that genes related
to periodontitis could play a role for the development of
diabetic vasculopathy. Because the tissue in our study is
without atherosclerosis and cellular infiltration, it seems
that the vascular smooth muscle cells themselves
may express an inflammatory phenotype. In agreement,
previous observations showed that vascular smooth
muscle cells produce a range of peptide factors that
have been suggested to play a role in diabetic vasculopa-
thy [9]. In addition, this finding is in line with previous
observations that vascular cells in diabetes may display
Figure 1 Interaction subnetwork of potential arterial disease-associated genes in patients with type 2 diabetes. The subnetwork consists
of 74 nodes and 166 edges. Red nodes represent upregulated genes, green nodes represent downregulated genes (P < 0.05), and white nodes
represent genes with P > 0.05. The z-score of the network is 9.23 (permute P = 0.01)
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to effects of toll-like receptors [31,32].
Over the past decades there has been much debate
regarding the relative importance of hyperinsulinism and
insulin resistance in vascular cells from diabetic patients
[33-36]. Interestingly, the insulin 2F-pathway, represent-
ing genes upregulated 2-fold by insulin stimulation of
skeletal muscle in healthy subjects [27], was significantly
downregulated in our study, supporting the idea that at
least some effects of insulin in vascular tissue are influ-
enced by insulin resistance and not by hyperinsulinism.
This is in agreement with several human and experimen-
tal observations [37-39].
Surprisingly, a triglyceride pathway was the most signifi-
cantly upregulated pathway using GO-Elite. Several
organs, such as muscle and liver, are known to accumulate
triglycerides in type 2 diabetes [40]; however, no informa-
tion concerning arterial tissue is currently available. Our
data are compatible with the hypothesis that accumulation
of triglycerides could also take place in the arterial wall.
Since the apoptotic process has been found to be regu-
lated in vascular smooth muscle cells from arterial tissue
from individuals with type 2 diabetes [12], it is of interest
that our data demonstrate an increased expression of the
apoptotic pathway using GO-Elite. The apoptotic path-
way may be regulated in arterial tissue in diabetes; how-
ever, further studies are warranted to assess the precise
implication of apoptosis in the pathogenesis of diabetic
arteriopathy. Of interest, also a pathway defined as genes
downregulated in glomeruli from patients with diabetic
nephropathy was downregulated in the arterial wall in
diabetes [41]. This observation may be an indication of a
common set of dysregulated genes present in both
micro- and macro-angiopathy in diabetes.
Although many detailed unique processes are sug-
gested to be implicated in the development of arterial
disease in diabetes, an understanding of the disease
mechanisms as an integrated whole may be warranted.
Network analysis provides a broad insight into biology in
the context of known functional interrelationships
among proteins. Our network analysis demonstrates a
statistically significant cluster of genes that are dysregu-
lated in the arterial wall in diabetes.
Looking for important hubs in the network, it is inter-
esting to note that the insulin receptor (INSR) appears,
although it is not itself regulated. It seems that many
genes, interacting with the receptor, are indeed regulated
in the arterial wall in diabetes, which is in accordance
Table 4 Topological values and number of interactors for
all genes in the network
Gene TPV NOI Gene TPV NOI Gene TPV NOI
ACTR3 0.625 2 FURIN 0.52 3 PTK2 0.20 8
ACVR1 0.7 2 FYN 0.27 6 PTMA 0 1
ARF1 0.5 2 GGA2 0 1 PTPN12 0.51 3
BCR 0.26 6 GRB10 0.39 4 PTPRF 0.36 3
BIRC4 0.33 3 IGF2 0.5 2 RABAC1 0.25 4
C1orf103 0 1 IGFBP3 0.33 3 RAP1A 0.33 3
CANX 0.27 5 INSR 0.17 10 RASA1 0.22 5
CASP10 0.33 3 IRS2 0.16 8 RHOA 0.33 3
CASP4 0 1 ITGAV 0.39 3 RIF1 0.5 2
CASP7 0.13 8 JAK2 0.24 8 RNF11 0 1
CD82 0.71 2 KRAS 0.59 2 ROCK1 0.5 2
CDC42 0.16 8 LRP1 0.32 5 RPS6KB1 0.57 2
DAB2 0 1 LYN 0.31 5 RRAS2 0.3 4
DCN 0.5 2 MAP3K7IP2 0 1 SMAD4 0.23 5
DVL2 0 1 MAX 0.25 4 SMURF2 0.24 5
EIF1B 0.31 4 MBIP 0 1 STK11 0.63 2
ELN 0.33 3 MMP14 0.41 3 STK24 0.5 2
EPOR 0.42 3 MMP2 0.32 4 SYNCRIP 0.5 2
F2 0.41 4 NCK1 0.39 3 TBK1 0.5 2
F8 0.31 5 NRAS 0.25 5 UBTF 0 1
FAM107A 0 1 OAT 0.63 2 UNC119 0.33 4
FAS 0.25 4 PARD3 0.24 5 VWF 0.57 3
FBLN1 0.5 2 PLEKHF2 0.25 4 YWHAQ 0.55 2
FBLN2 0 1 PPP1CB 0.5 2 YWHAZ 0.36 3
FRS2 0.39 3 PRKAR1A 0 1
TPV: topological value; NOI: number of interactors. The TPV is a number
between 0-1. Nodes that have one neighbor are assigned a topological value
of 0
Table 5 Important cardiometabolic hubs and their interactors in non-atherosclerotic diabetic arterial tissue
Hub Interactor Hub Interactor Hub Interactor Hub Interactor
INSR ARF1 CDC42 ACTR3 IRS2 EPOR SMAD4 FBLN1
FRS2 C1ORF103 INSR MAX
GRB10 CASP7 KRAS NRAS
IGF2 OAT NRAS PARD3
IRS2 PARD3 PTPRF RRAS2
JAK2 RIF1 UBTF MMP2 DCN
PTK2 RPS6KB1 YWHAQ IGFBP3
PTPN12 UNC119 YWHAZ ITGAV
RASA1 MMP14
SYNCRIP
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p l a yar o l ei nd i a b e t i ca r t e r i a ld i s e a s e( 3 5 - 3 7 ) .A n o t h e r
r e l e v a n th u bi sS M A D 4 ,w h i c hs e e m st oh a v ea ni m p o r -
tant place in the network, interacting both with intracel-
lularly expressed genes like RRAS2 and PARD3, as well
as an extracellular matrix gene, fibulin-1 (FBLN1).
SMAD4 is an important intracellular signaling molecule
in the TGF-beta system which is in agreement with other
observations showing that this system is involved in the
development of matrix accumulations in diabetic compli-
cations [42,43]. A recent transcriptome analysis of
human diabetic kidney disease pointed towards CDC42
signaling as an important dysregulated pathway [44],
which is in accordance with the presence of CDC42 as an
important hub in the network we present here. MMP2 is
an important hub in the network with connections to
other relevant genes including MMP14, DCN and
ITGAV. This part of the network is in agreement with
other previously reported data showing that MMP2 is
dysregulated in the arterial wall in diabetes [45] and
seems to indicate that matrix remodeling may be an
important feature of the non-atherosclerotic arterial dis-
ease seen in diabetes.
Conclusions
We used transcriptional profiling on well-defined non-
atherosclerotic arterial samples from diabetic individuals.
Using pathway and network analysis, our data display a
statistically significant cluster of dysregulated genes in the
arteries of diabetic patients, which is in accordance with
the presence of a diffuse diabetic macroangiopathy, similar
to the diabetic microangiopathy. Our approach has not
previously been used, but point towards dysregulated
pathways related to matrix metabolism, triglyceride synth-
esis, inflammation, as well as insulin signaling and apopto-
sis. Dysregulated gene interactions and pathways in the
cells of the arterial wall in diabetes may play important
roles in the arterial response to injury and atherosclerosis.
Data deposition footnote
Data are available from GEO (http://www.ncbi.nlm.nih.
gov/geo, Accession No. GSE13760).
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